

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number  
**WO 2005/018628 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/19,**  
31/235, C07C 323/00

(21) International Application Number:  
PCT/US2004/026561

(22) International Filing Date: 16 August 2004 (16.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/496,533 20 August 2003 (20.08.2003) US

(71) Applicant (for all designated States except US): **WELL-  
STAT THERAPEUTICS CORPORATION** [US/US];  
930 Clopper Road, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHARMA, Shalini**  
[US/US]; 211 Bristol Down Drive, Gaithersburg, MD 20878  
(US). **VONBORSTEL, Reid, W.** [US/US]; 8310 Fox Run,  
Potomac, MD 20854 (US). **HODGE, Kirvin, L.** [US/US];  
8115 Mississippi Road, Laurel, MD 20724 (US).

(74) Agent: **KREISLER, Lewis, J.**; Legal Department, 930  
Clopper Road, Gaithersburg, MD 20878 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS



(57) Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0 or 1; q is 0 or 1; t is 0 or 1; R<sup>5</sup> is alkyl having from 1 to 3 carbon atoms; R<sup>9</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and X is -CH<sub>2</sub>-, Q is -OR<sup>1</sup> and R<sup>1</sup> is methyl or ethyl; or X is -CH<sub>2</sub>CR<sup>12</sup>R<sup>13</sup>- or -CH<sub>2</sub>CH(NHAc)-wherein each of R<sup>12</sup> and R<sup>13</sup> is independently hydrogen or methyl, Q is OR<sup>1</sup> and R<sup>1</sup> is hydrogen or alkyl having from 1 to 7 carbon atoms; or X is -CH<sub>2</sub>CH<sub>2</sub>- and Q is NR<sup>10</sup>R<sup>11</sup> wherein one of R<sup>10</sup> and R<sup>11</sup> is hydrogen, alkyl having from 1 to 3 carbon atoms or hydroxy, and the other is hydrogen. Alternatively, when R<sup>1</sup> is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

WO 2005/018628 A1